FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека пептидов

FDA-регулируемый компонент

Этот компонент FDA одобрён или регулируется. Покупка без действительного рецепта может нарушить федеральное законодательство. Убедитесь, что вы соблюдаете все юридические требования в вашем регионе.

Semaglutide

Ozempic / Wegovy / Rybelsus

Weight Loss & Metabolic

Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.

Механизм действия

GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.

Протоколы исследований

Только для исследовательских целей. Не медицинская консультация.

Typical research protocols use 0.25mg weekly for 4 weeks, escalating to 0.5mg weekly, then 1mg weekly. Maximum studied dose is 2.4mg weekly for weight management.

Примечания к исследованиям

Clinical Research Status

FDA-approved for type 2 diabetes (Ozempic 2017, Rybelsus 2019) and obesity (Wegovy 2021). Ongoing Phase 3 trials for NASH/MASH (liver disease), heart failure with preserved ejection fraction, Alzheimer's disease, and substance use disorders. SELECT trial demonstrated 20% cardiovascular risk reduction in overweight patients.

Key Published Findings

STEP trials demonstrated 15-17% average body weight loss over 68 weeks at 2.4mg weekly dose. SUSTAIN trials showed HbA1c reductions of 1.5-1.8% in type 2 diabetes. PIONEER trials established efficacy of oral formulation. FLOW trial showed 24% reduction in kidney disease progression. STEP HFpEF trial showed significant improvement in heart failure symptoms and physical limitations.

Safety Profile

Most common side effects are gastrointestinal: nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). These typically diminish with dose titration. Black box warning for thyroid C-cell tumors (observed in rodents, not confirmed in humans). Reports of pancreatitis, gallbladder events, and retinopathy complications. Post-marketing reports of suicidal ideation under investigation.

Drug Interactions & Contraindications

Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Delays gastric emptying, which may affect absorption of other oral medications. Caution with insulin or sulfonylureas (increased hypoglycemia risk). Not recommended during pregnancy or breastfeeding.

Comparison to Related Compounds

More potent and longer-acting than liraglutide (Victoza/Saxenda). Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist showing slightly greater weight loss (up to 22.5% in SURMOUNT trials). Retatrutide (triple agonist) in Phase 3 trials shows even greater efficacy. CagriSema (semaglutide + cagrilintide) in Phase 3 trials combines GLP-1 and amylin pathways.

Community Observations

Extreme demand has led to widespread shortages and compounding pharmacy versions of varying quality. Counterfeit products are a significant concern. Users commonly report dramatic appetite suppression, food noise reduction, and altered relationship with alcohol. Muscle loss during weight loss is a frequently discussed concern — resistance training and adequate protein intake are widely recommended.

Половая жизнь

~7 days

Реконституция

Bacteriostatic water (BAC)

Хранение

Лиофилизированный

Room temperature up to 36 months. Protect from light.

Реконститутированный

Refrigerate 2-8C. Use within 56 days.

Юридический статус США

FDA-approved (Rx only)

Также известен как

OzempicWegovyRybelsus

Часто задаваемые вопросы

Что такое Semaglutide?

Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes (Ozempic, Rybelsus) and later approved for chronic weight management (Wegovy). It is a 31-amino acid peptide analog of human GLP-1 with a half-life of approximately 7 days, enabling once-weekly dosing. It has become one of the most commercially successful peptide drugs in history, with combined annual revenues exceeding $20 billion.

Как действует Semaglutide?

GLP-1 receptor agonist that mimics incretin hormones. Enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. Centrally reduces appetite through hypothalamic signaling.

Каков регуляторный статус Semaglutide в США?

FDA-approved (Rx only)

Каков период полувыведения Semaglutide?

~7 days

Как ещё называют Semaglutide?

Ozempic, Wegovy, Rybelsus

Peptide Contacts предоставляет исследовательские сводки только для информационных целей. Мы не хостим, распространяем или одобряем документацию поставщиков. Все сертификаты анализа, GMP-сертификаты и коммуникации с поставщиками должны быть запрослены и проверены непосредственно покупателем. Ничто на этом платформе не является юридическим, медицинским или профессиональным советом. Пользователи самостоятельно отвечают за проверку квалификаций поставщиков и обеспечение соответствия всем применимым местным, штатным и федеральным законам перед покупкой любых исследовательских химикатов. Использование этой платформы означает принятие полной личной ответственности.

Прочитать полное заявление о неприкосновенности